Do bisphenol A and butylparaben disrupt estrogen signaling and metabolic regulation?

Bisphenol A (BPA) and butylparaben are widely distributed synthetic compounds that act as endocrine-disrupting chemicals, perturbing systemic hormonal balance and metabolic health through distinct nuclear and membrane-bound receptor pathways.

Estrogenic receptor interference

• BPA receptor kinetics: BPA acts as a partial agonist on classical estrogen receptors ERα and ERβ with an affinity approximately 1,000- to 10,000-fold weaker than 17β-estradiol. However, it binds to membrane-bound GPER and estrogen-related receptor gamma (ERRγ) with high nanomolar affinity ($K_d \approx$ 5.5–5.7 nM), preserving its constitutive activity and triggering rapid non-genomic signaling.
• Butylparaben cellular activation: Butylparaben binds ERα and ERβ with an affinity four to five orders of magnitude lower than 17β-estradiol. Despite this low potency, it drives ER dimerization, nuclear translocation, and estrogen response element binding, promoting cellular proliferation in estrogen-responsive tissues.

Metabolic and adipogenic disruption

• Pancreatic and tissue inflammation: BPA disrupts glucose homeostasis by closing ATP-sensitive potassium channels in pancreatic β-cells at nanomolar concentrations. This induces rapid insulin hypersecretion, leading to chronic insulin resistance, and engages the aryl hydrocarbon receptor (AhR) to drive oxidative stress.
• Adipogenesis and stem cell skewing: Butylparaben functions as a direct PPARγ agonist. This ligand activation drives the transcriptional upregulation of C/EBPα and FABP4, which selectively commits multipotent mesenchymal stem cells toward the adipocyte lineage at the expense of osteogenesis, while concurrently altering the secretion of leptin, adiponectin, and resistin.

Bottom line

• Both BPA and butylparaben disrupt hormone signaling and metabolic regulation via low-affinity classical estrogen receptor binding coupled with high-affinity interactions at non-classical receptor sites (GPER, ERRγ, and PPARγ) that drive insulin hypersecretion and adipogenesis.